The majority of colorectal cancer patients are not responsive to immune checkpoint
blockade (ICB). The interferon gamma (IFNγ) signaling pathway drives spontaneous and …

Colorectal cancer (CRC) is the third most common malignancy and the second most
common cause of cancer-related mortality worldwide. A total of 20% of CRC patients present …

Background FOLFOX is a combinational regimen of folinic acid (FnA, FOL), fluorouracil (5-
Fu, F) and oxaliplatin (OxP, OX), and has been long considered as the standard treatment of …

Abstract T cell factor‐1 (TCF‐1)(encoded by the TCF7 gene) is a transcription factor that
plays important role during the T cell development and differentiation for T cell to exercise its …

Immunotherapy is a new pillar of cancer therapy that provides novel opportunities to treat
solid tumors. In this context, the development of new drugs targeting immune checkpoints is …

Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for several
malignancies. While the use of single-agent or combined ICIs has achieved acceptable …

Neoadjuvant chemoradiotherapy (NACRT) or chemotherapy (NACT) followed by radical
resection and then adjuvant therapy is considered the optimal treatment model for locally …

While colorectal cancers (CRC) are paradigmatic tumors invaded by effector memory
lymphocytes, the mechanisms accounting for the relative resistance of MSI negative CRC to …

Background A large proportion of the patients with cancer do not respond to
immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic …

In recent years, there has been a significant increase in the study of own and foreign human
factors favoring the development of different types of cancer, including genetic and …